JNJ

Business profile & competitive position

Johnson & Johnson is a Healthcare holding company in the Drug Manufacturers - General industry. Through subsidiaries with approximately 138,200 full-time-equivalent employees worldwide, it researches, develops, manufactures, and sells healthcare products across two segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism. MedTech develops products used in cardiovascular, orthopaedics, surgery, and vision procedures. These products are distributed to retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare professionals in virtually all countries of the world.

The financial profile suggests a wide-moat, capital-efficient franchise. The net margin is 21.5%, while return on equity stands at 25.7%. Those figures are well above what commodity-style healthcare companies typically generate, pointing to durable pricing power and strong operational execution. The business is also unusually concentrated for a company of its size: the 10-K disclosure shows DARZALEX/DARZALEX FASPRO contributed approximately 15.0% of 2025 total revenues, STELARA approximately 6.5%, and TREMFYA approximately 5.5%. Taken together, those three blockbusters account for roughly 27% of total revenue, meaning J&J's competitive position is tied closely to a handful of high-value therapeutics.

Financial posture

J&J currently carries a market capitalization of $663.3 billion and trades at a price-to-earnings ratio of 31.8. Profitability metrics remain robust: net margin at 21.5% and ROE at 25.7%. The beta of 0.23 is extremely low relative to the broad market, which fits the stock's classification as a defensive large-cap healthcare name. At the current snapshot, the stock price is $275.23, comfortably above the 50-day exponential moving average of $260.66, while the RSI is 60.6.

The valuation at 31.8x earnings implies the market is assigning a meaningful premium to J&J's earnings stream—consistent with a company that combines pharmaceutical growth franchises with a stable medical-device cash-flow base. The 21.5% net margin is particularly notable in a sector where R&D, regulatory, and manufacturing costs are substantial, and the 25.7% ROE indicates that management is generating strong returns on the equity base despite the company's scale.

Strategic priorities & outlook

J&J's most recent 10-K outlines several genuine operational priorities. The most concrete near-term corporate action is the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months of the announcement. That implies execution roughly in the first half of 2027 through late 2027. The filing also emphasizes human capital management organized around three pillars: attracting and recruiting top talent, developing and retaining top talent, and empowering and inspiring talent. Supporting that is a Credo-based culture focused on innovation, health, well-being, safety, inclusion, and belonging, plus a learning culture built through tools such as J&J Learn and the annual Global Learning Day.

On the product side, the 10-K flags that continued global biosimilar launches against STELARA are expected to keep pressuring STELARA sales. It also notes that worldwide sales do not reflect significant seasonality, but fourth-quarter spending is typically heavier due mainly to advertising and research and development decisions. Investors watching the 2026-10-13 earnings report may want to pay particular attention to commentary on the Orthopaedics separation timeline, biosimilar erosion in immunology, and any update on DARZALEX momentum.

Macro & geopolitical exposure

As a Drug Manufacturers - General company, J&J is exposed to the macro and geopolitical vectors that shape the global pharmaceutical and medical-device industries. These include drug-pricing regulation and reimbursement policy—especially Medicare and Medicaid dynamics in the United States—FDA approval timelines, patent cliffs, and biosimilar competition. The data already shows biosimilar competition hitting STELARA, which is a textbook pharmaceutical-industry headwind.

Because the company distributes products in virtually all countries of the world, it also faces currency-translation risk, cross-border trade policy changes, and supply-chain considerations for active pharmaceutical ingredients and medical-device components. Tariffs or trade restrictions on medical goods could affect the MedTech segment's cost structure, while regulatory shifts in major international markets could alter the commercial environment for Innovative Medicine products.

Recent developments

On 2026-09-07, four real news items appeared. Zacks.com published "Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?", framing J&J as the stability-oriented alternative to a higher-growth pharmaceutical peer. 247wallst.com asked "Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?", again placing J&J in the defensive-stock bucket. Defenseworld.net reported that EFG International AG lowered its stake in Johnson &J, and Blue Edge Capital LLC trimmed its holdings in the same ticker. The institutional-trimming headlines contrast with the broader media narrative that still treats J&J as a defensive anchor.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, J&J beat estimates in seven of eight quarters—a 100% beat rate within that measured window—with an average earnings surprise of 3.4%. The average 5-day price move in the five trading days after earnings was 0.67% to the upside, classified as an upward post-earnings drift.

The most recent four quarters show the nuance behind the averages. On 2026-07-15, JNJ reported actual EPS of $2.90 versus the estimate of $2.84, a 2.1% surprise; the stock rose 1.19% the next day and 3.49% over the following five days. On 2026-04-14, actual EPS of $2.70 beat the $2.68 estimate by 0.7%, yet the stock fell 0.6% the next day and declined 5.81% over the next five sessions. On 2026-01-21, actual EPS of $2.46 matched the $2.46 estimate exactly—an inline result—and the stock still gained 0.22% the next day and 4.45% over five days. On 2025-10-14, actual EPS of $2.80 beat the $2.76 estimate by 1.4%, with the stock rising 0.17% the next day and 0.54% over five days.

That pattern shows that beating the consensus does not guarantee a positive immediate reaction, and that post-earnings drift can be modest and variable. The next scheduled report is 2026-10-13 before the open, with the current consensus EPS estimate at $2.90.

For a deeper dive into how institutional analysts are currently weighting J&J's valuation, earnings setup, and sector positioning ahead of the October 2026 report, you can review the full institutional verdict on the ticker page.